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Interleukin-15 (IL-15) regulates the development andmaintenance of memory CD8+ T cells. Paradoxically, we previously reported
that IL-15 could enhance CD8+ T-cell responses to IL-12, a proin�ammatory cytokine required for optimal priming of eﬀector
CD8+ T cells. To expand the physiological relevance of these �ndings, we tested IL-15 for its ability to enhance T-cell responses to
bacterial CpG. Expectedly, CpG enhanced the production of IFN-𝛾𝛾𝛾𝛾 by CD8+ T cells polyclonally activated with anti-CD3. However,
addition of IL-15 to CpG-stimulated cultures led to a striking increase in IFN-𝛾𝛾𝛾𝛾 production. e eﬀect of CpG and IL-15 was also
evident with CD8+ T cells recovered from mice infected with the parasite Trypanosoma cruzi (T. cruzi) and restimulated with
antigen. e observed synergy between CpG and IL-15 occurred in an IL-12-dependent manner, and this eﬀect could even be
demonstrated in cocultures of activated CD8+ T cells and CD4+CD25+ regulatory T cells. Although IFN-𝛾𝛾𝛾𝛾 was not essential for
CpG-induced IL-12, the ability of CpG and IL-15 to act on CD8+ T cells required expression of the IFN-𝛾𝛾𝛾𝛾-inducible transcription
factor T-bet. ese data have important implications for development of vaccines and design of therapies to boost CD8+ T-cell
responses to infectious agents and tumors.
1. Introduction
Interleukin-15 (IL-15) is a member of the common 𝛾𝛾𝛾𝛾 chain
cytokine family that is important for development and
maintenance of memory CD8+ T cells [1, 2]. IL-15 has shown
promise in its ability to enhance vaccine-mediated immunity
against pathogens. For example, vaccination against the
intracellular protozoan parasiteTrypanosoma cruzi (T. cruzi),
the causative agent of human Chagas disease, was improved
when combined with a plasmid encoding IL-15 [3]. IL-15
can also promote the eﬀector functions of CD8+ T cells
[4]. For instance, we previously demonstrated that IL-15
enhances IFN-𝛾𝛾𝛾𝛾 production by human CD8+ T cells by
increasing T cell responsiveness to IL-12 [5]. Others have
demonstrated that adoptive immunotherapy of solid tumors
was enhanced by inducing a lymphopenic environment in
the tumor-bearing host prior to adoptive transfer of T cells,
and that IL-15-mediated lymphopenia-induced proliferation
(as well as proin�ammatory cytokines released in response
to total body irradiation) was an important component of
eﬀective therapy [6].
CpG motifs are unmethylated dinucleotides that are
present in bacterial DNA, and they were previously dis-
covered to possess powerful immunostimulatory properties
[7, 8]. Binding of CpG to Toll-like receptor 9 (TLR-9) on
antigen-presenting cells (APCs) induces APC maturation
through up-regulation of MHC class II, and the costimula-
tory molecules CD40 and CD86 [9, 10]. CpG can also stim-
ulate production of proin�ammatory cytokines, particularly
IL-12, which promotes T-cell priming and diﬀerentiation
[11]. us, CpG has the potential to enhance both innate
and adaptive immunity and represent a powerful agent that
can be used as an adjuvant for vaccine-induced immunity.
Indeed, the immunostimulatory properties of bacterial CpG
have been recapitulated by the use of synthetic oligodeoxynu-
cleotides (ODNs). For example, synthetic CpG have been
shown to increase both natural and vaccine-induced immune
responses to T. cruzi [12].
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Based on our previous studies with IL-15, and to examine
the eﬃcacy of IL-15 in a clinically relevantmanner, we sought
to determine as a proof-of-concept if IL-15 could synergize
with CpG to enhance CD8+ T-cell responses. We report
that the combination of IL-15 and CpG led to a signi�cant
increase in IFN-𝛾𝛾𝛾𝛾 production by CD8+ T cells, including
the enhancement of IFN-𝛾𝛾𝛾𝛾 production by T. cruzi-speci�c
CD8+ T cells in an antigen-speci�c manner. Mechanistically,
the observed synergy between IL-15 and CpG was critically
dependent uponAPC-derived IL-12.epotency of the com-
bined eﬀect of CpG-induced IL-12 and IL-15was also evident
in cocultures of CD8+ T cells and naturally occurring (i.e.,
thymus-derived), CD4+CD25+ regulatory T cells (nTreg),
which are well known for their potent ability to suppress
T-cell activation. Impressively, both proliferation and IFN-
𝛾𝛾𝛾𝛾 production were markedly enhanced by these cytokines
even in the presence of high numbers of nTreg. Although
IFN-𝛾𝛾𝛾𝛾was not essential for CpG-induced IL-12, the ability of
CpG and IL-15 to act on CD8+ T cells required expression
of the IFN-𝛾𝛾𝛾𝛾-inducible transcription factor T-bet. ese
results have important implications for future development
of preventative vaccines that combine the potency of TLR
agonists such as CpGwith cytokines known to promote long-
term memory.
2. Materials andMethods
2.1. Mice and Infections. Age-matched female C57BL/6,
Tbx21−/−, B6.129 IL12p35−/−, and Ifng−/−micewere obtained
frome Jackson Laboratory and were used between six and
eight weeks of age. Mice were housed in an Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC)- accredited facility under pathogen-free condi-
tions and used in accordance with an Institutional Animal
Care and Use Committee- (IACUC)- approved protocol. For
infections, mice were injected intraperitoneally with 1 × 106
tissue-culture-derived T. cruzi trypomastigotes (CL strain).
2.2. �eagents and Cell Puri�cations. Recombinant human IL-
15 was purchased from R&D Systems and used at 1 ng/mL,
10 ng/mL, or 100 ng/mL. CpG ODN 231627 was purchased
from TIB MolBiol. For antigen-speci�c ex vivo recall re-
sponses to T. cruzi, Tskb20 peptide was used. Tskb20 pep-
tide (ANYKFTLV) was synthesized by and purchased from
Abgent (San Diego, CA). For in vitro neutralization of IFN-𝛾𝛾𝛾𝛾
and IL-12, LEAF-puri�ed anti-IFN-𝛾𝛾𝛾𝛾 (clone XMG1.2, Biole-
gend) and anti-IL-12p40 (clone C17.8, Biolegend) antibodies
were used at a concentration of 5 𝜇𝜇𝜇𝜇g/mL. CD8+ T cells were
isolated from naïve and T. cruzi-infected mice by positive
selection using CD8 Microbeads (MACS, Miltenyi) and
purity was greater than 95%.y1.2− splenocytes were isolat-
ed by depleting y1.2+ cells from naïve or T. cruzi-infected
mice using CD90.2 Microbeads and LD columns (MACS,
Miltenyi) and purities were greater than 98%. CD8+ T cells
were activated with soluble anti-CD3 (0.1𝜇𝜇𝜇𝜇g/mL, 145-2C11).
CD4+CD25+ nTreg were prepared from pooled lymph nodes
of naïve mice using Treg isolation kits (Miltenyi Biotec).
Purity of nTreg populations (CD4+CD25+) was routinely
checked by FACS and greater than 93% and puri�ed nTreg
expressed Foxp3 as determined by intracellular FACS.
2.3. In Vitro and Ex Vivo Cell Cultures. 2 × 105 CD8+ T cells
from naïve mice were cocultured with 2 × 106 live y1.2-
depleted splenocytes in complete RPMI 1640 (10% FBS,
10mM Hepes, 1 IU/mL penicillin and 100𝜇𝜇𝜇𝜇g/mL strepto-
mycin, 2mML-glutamine, 1×10−5M2-𝛽𝛽𝛽𝛽-mercaptoethanol).
Cells were stimulated with 0.1 𝜇𝜇𝜇𝜇g/mL of LEAF-puri�ed anti-
CD3 in the presence of 0.5𝜇𝜇𝜇𝜇MCpG and recombinant human
IL-15 for 72 hours. For antigen-speci�c responses, 2 × 106
splenocytes from T. cruzi-infected mice were cultured with
Tskb20 peptide (1 ng/mL) for 72 hours.
2.4. CFSE Labeling. Subsequent to column puri�cation,
CD8+ T cells were labeled with CFSE by incubating T cells
at 100 × 106 cells/mL in 5 𝜇𝜇𝜇𝜇M of CFSE/HBSS for 5 minutes at
room temperature. Labeling was quenched by addition of an
equal volume of fetal bovine serum. Cells were washed and
resuspended in complete RPMI.
2.5. Coculture Assay with Treg. Cocultures of CFSE-labeled
CD8+ T cells, APC, and Treg were established by adding
2.5 × 105 CD8+ T cells, 1 × 106 APC, and decreasing
numbers of Treg (starting with a 1 : 1 suppressor : responder
ratio) per mL of complete RPMI to wells of 48-well plates.
Low-endotoxin/azide-free anti-CD3 antibody (LEAF, 2C11,
Biolegend) was used at 0.5 𝜇𝜇𝜇𝜇g/mL. In addition, recombinant
human IL-15 (R&D Systems) and recombinant mouse IL-12
(R&D Systems) were used at 1 ng/mL and 0.1 ng/mL, respec-
tively. Aer 72 hours, cells were harvested and supernatants
stored frozen at −80∘C until use. Cells were stained with anti-
CD8 allophycocyanin (Biolegend), and 30,000 live events
were analyzed on a Beckman-Coulter FC500 instrument.
�uanti�cation of cell division was determined by gating on
either CFSE+ cells or CD8+ T cells and determining the
frequency of cells in each gate/CFSE peak. Supernatants were
tested for IFN-𝛾𝛾𝛾𝛾 as described below.
2.6. Measurement of Cytokines. Cell culture supernatants
were collected aer 72 hours, or in some cases aer 24 hours,
and analyzed for the presence of IFN-𝛾𝛾𝛾𝛾 and IL-12p40 using
Biolegend’s ELISA MAX Standard Sets according to their
recommendations.
2.7. Statistical Analysis. Data were analyzed using one-way
ANOVA, Tukey multiple comparison procedures (SigmaPlot
11.0, Systat Soware, Inc.). A 𝑃𝑃𝑃𝑃 value <0.05 was considered
signi�cant. Data are represented asmeans±SD of experimen-
tal groups.
3. Results
3.1. IL-15 and CpG Synergize to Enhance IFN-𝛾𝛾𝛾𝛾 Production
by CD8+ T Cells. Previous studies have demonstrated the
importance of IL-15 in regulating the development and
function of memory CD8+ T cells. Additionally, we reported
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F 1: e synergistic eﬀects of IL-15 and CpG enhance CD8+ T cell IFN-𝛾𝛾𝛾𝛾 production. (a) Naïve CD8+ T cells were cocultured with live
y1.2-depleted splenocytes and anti-CD3 (0.1 𝜇𝜇𝜇𝜇g/mL) with increasing concentrations of recombinant human IL-15. Aer 72 hours culture
supernatants were harvested and tested by ELISA for IFN-𝛾𝛾𝛾𝛾. (b) CD8+ T cells andy1.2-depleted splenocytes were coculturedwith anti-CD3
for 72 hours in the presence of IL-15 (1 ng/mL), CpG (0.5 𝜇𝜇𝜇𝜇M), or IL-15+CpG. Cell culture supernatants were then harvested and IFN-𝛾𝛾𝛾𝛾
levels were determined by ELISA. (c) Intracellular cytokine staining and �ow cytometric analysis comparing CD8 expression (𝑥𝑥𝑥𝑥-axis) versus
IFN-𝛾𝛾𝛾𝛾 production (𝑦𝑦𝑦𝑦-axis) following 72 hour culture with IL-15+CpG. Numbers represent the percentage of CD8+ T cells that are IFN-𝛾𝛾𝛾𝛾+.
Results are representative of three independent experiments and are expressed as mean ± SD. ∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃; ∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃; NS: not signi�cant.
that IL-15 could enhance human T-cell responses to IL-12.
To assess the physiological relevance of this eﬀect, we sought
to determine whether IL-15 and CpG could augment IFN-𝛾𝛾𝛾𝛾
production by TCR-activated CD8+ T cells. At low doses
(1–10 ng/mL), IL-15 alone had very little impact on IFN-𝛾𝛾𝛾𝛾
production (Figure 1(a)). However, when 100 ng/mL of IL-15
was used, there was a signi�cant increase in the level of IFN-𝛾𝛾𝛾𝛾
production (Figure 1(a)). us, to minimize direct eﬀects of
IL-15 on cytokine production, we used 1 ng/mL of IL-15 for
all subsequent experiments. We next evaluated the combined
eﬀects of IL-15 and CpG on IFN-𝛾𝛾𝛾𝛾 production by CD8+ T
cells. As expected, addition of IL-15 to anti-CD3-stimulated
CD8+ T cells did not increase in IFN-𝛾𝛾𝛾𝛾 production. However,
addition of CpG led to a signi�cant increase in TCR-induced
IFN-𝛾𝛾𝛾𝛾 production compared to anti-CD3 stimulation only
(Figure 1(b)). Surprisingly, the addition of both IL-15 and
CpG to CD8+ T-cell cultures stimulated with anti-CD3
resulted in strong enhancement of IFN-𝛾𝛾𝛾𝛾 production
(Figure 1(b)). Importantly, the increase in IFN-𝛾𝛾𝛾𝛾 production
represented a synergistic eﬀect. To demonstrate that the eﬀect
of IL-15 and CpG was on CD8+ T cells only, intracellular
cytokine staining/FACS were performed. In agreement with
the above results, the percentage of CD8+ T cells producing
IFN-𝛾𝛾𝛾𝛾 was signi�cantly increased following treatment with
both IL-15 and CpG (Figure 1(c)). In contrast, CD8-negative
cells (which include CD4+T cells and NK1.1 cells) failed
to show a similar increase (Figure 1(c)). ese results are
further supported by the fact that less than 1% of these cells
were present in CD8+ T-cell cultures and did not produce
signi�cant amounts of IFN-𝛾𝛾𝛾𝛾 following culture with IL-15
and CpG. Furthermore, y1.2-depleted (T-cell-depleted)
splenocytes cultured in the presence of IL-15+CpG produced
little IFN-𝛾𝛾𝛾𝛾 (𝑃𝑃0.1 ng, not shown), indicating that CD8+ T
cells are the main source of IFN-𝛾𝛾𝛾𝛾 in these cultures. ese
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F 2:e synergistic eﬀects of IL-15 and CpG enhance T. cruzi-speci�c IFN-𝛾𝛾𝛾𝛾 production by CD8+ T cells. C57BL/6 mice were infected
withTrypanosoma cruzi. On day 9 postinfection,mice were euthanized and spleens harvested. (a) Splenocytes were cultured for 72 hours with
Tskb20 peptide (1 ng/mL) to induce an antigen-speci�c CD8+ T cell response. Culture supernatants were tested by ELISA to determine the
levels of IFN-𝛾𝛾𝛾𝛾 production. (b) Puri�ed CD8+ T cells were cultured in the presence of IL-15, CpG, or IL-15+CpG for 72 hours. Culture
supernatants were tested by ELISA for IFN-𝛾𝛾𝛾𝛾. ∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃; ∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃; NS: not signi�cant. Results are representative of at least three
independent experiments with two mice per group and are expressed as mean ± SD.
results demonstrate that IL-15 can enhance the ability of
CpG to promote IFN-𝛾𝛾𝛾𝛾 production by TCR-activated CD8+
T cells, without directly inducing IFN-𝛾𝛾𝛾𝛾. ese data are
consistent with a report in which the combination of IL-15
and CpG-enhanced CD69 expression on human T cells [6].
3.2. IL-15 and CpG Can Synergize to Increase the T-Cell IFN-
𝛾𝛾𝛾𝛾 Response to the Intracellular Parasite T. cruzi in an Antigen-
Speci�c�anner. Because of the potent synergy between CpG
and IL-15 in enhancing IFN-𝛾𝛾𝛾𝛾production byT cells polyclon-
ally stimulatedwith anti-CD3, we next wanted to determine if
this eﬀect could be extended to antigen-speci�c CD8+ T cells.
To test this, we utilized a murine model of T. cruzi infection.
Infection with the intracellular protozoan parasite T. cruzi
elicits a strong CD8+ T-cell-mediated IFN-𝛾𝛾𝛾𝛾 response that
is necessary for host protection. Previous studies have also
shown that successful vaccine-induced immunity against T.
cruzi induces a strong CD8+ T-cell and IFN-𝛾𝛾𝛾𝛾 response [13–
16]. Hence, mice were infected with T. cruzi and splenocytes
harvested 9 days postinfection (day 9 p.i.). is time point
was chosen because we can detect T. cruzi-speci�c CD8+ T
cells in infected mice by FACS on this day [17], and it has
been demonstrated to peak at approximately 10–12 d.p.i. [18].
Splenocytes from uninfected and T. cruzi-infected mice were
subsequently restimulated with Tskb20, a peptide previously
identi�ed as an immunodominant epitope of the CD8+
T-cell response to T. cruzi. Addition of IL-15 to Tskb20
peptide-stimulated splenocyte cultures did not signi�cantly
increase IFN-𝛾𝛾𝛾𝛾 production. However, similar to its eﬀects on
polyclonally activated CD8+ T cells from uninfected mice,
CpG induced a signi�cant increase in Tskb20 antigen-speci�c
IFN-𝛾𝛾𝛾𝛾. Addition of IL-15 to CpG led to a further increase
in IFN-𝛾𝛾𝛾𝛾 production by Tskb20-speci�c CD8+ T cells, albeit
not as signi�cant as that observed with na�ve T cells (Figure
2(a)). Since these T cells were derived from infectedmice and
highly activated, we wanted to determine whether IL-15 and
CpG could drive IFN-𝛾𝛾𝛾𝛾 production in the absence of TCR
stimulation. To test this, CD8+ T cells were puri�ed from
T. cruzi-infected mice and cultured in the presence of IL-15,
CpG, or IL-15+CpG.Although the levels of IFN-𝛾𝛾𝛾𝛾production
were lower without TCR stimulation, the synergistic eﬀects
of IL-15 and CpG were still evident (Figure 2(b)). us,
comparable to anti-CD3-stimulated CD8+ T cells, IL-15
and CpG can synergize to promote antigen-speci�c IFN-
𝛾𝛾𝛾𝛾 production by CD8+ T cells. Of note, IFN-𝛾𝛾𝛾𝛾 levels from
y1.2-depleted (T cell-depleted) splenocytes cultured in the
presence of IL-15/CpGwereminimal (𝑃𝑃1 ng/mL, not shown),
indicating aminor contribution of APC to IFN-𝛾𝛾𝛾𝛾 production.
3.3. e Enhancement of T-Cell IFN-𝛾𝛾𝛾𝛾 Production by IL-15
and CpG Requires IL-12 Production by Antigen-Presenting
Cells. Previously it was shown that IL-15 is essential for
CpG-induced activation of dendritic cells, including the
production of IL-12 [19]. erefore, we sought to determine
whether the synergistic eﬀect of IL-15 and CpG was a
consequence of increased IL-12 production by APC. To test
this, APC cultureswere prepared by depletion ofy1.2+ cells
from splenocytes obtained from either uninfected orT. cruzi-
infected mice, and subsequently cultured with IL-15, CpG,
or IL-15 plus CpG. Indeed, stimulation of APC with CpG
resulted in a signi�cant increase in IL-12p40 production.
Surprisingly, IL-15 alone had no signi�cant eﬀect on IL-
12p40 production. Furthermore, the combination of IL-15
and CpG did not further increase the levels of IL-12p40 over
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F 3: IL-12 is required for CpG+IL-15-mediated enhancement of IFN-𝛾𝛾𝛾𝛾 production. (a) Splenocytes were harvested from the spleens
of uninfected (�lled bars) or T. cruzi-infected wild-type (open bars) mice on day 9 p.i. y1.2-depleted splenocytes were then cultured in
the presence of IL-15, CpG, or both IL-15 and CpG. Aer 72 hours, culture supernatants were harvested and tested for IL-12p40 by ELISA.
(b) CD8+ T cells and live y1.2-depleted APC were cocultured with anti-CD3 for 72 hours in the presence of IL-15, CpG, IL-15+CpG,
IL-15+CpG+isotype antibody, or IL-15+CpG+anti-IL-12p40 antibody. Cell culture supernatants were then harvested and IFN-𝛾𝛾𝛾𝛾 levels were
determined by ELISA. (c) Splenocytes from wild-type (�lled bars) or IL-12p35−/− (open bars) mice infected with T. cruziwere cultured for 72
hours with Tskb20 peptide. ∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃; ∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃; NS: not signi�cant. Results are representative of three to four independent experiments
with at least two mice per group and expressed as mean ± SD.
that of CpG alone (Figure 3(a)). us, these data show that
although CpG induces IL-12 secretion, synergy between IL-
15 and CpG is not the result of an IL-15-mediated increase in
IL-12 production.
Although CpG are known to stimulate IL-12 production,
it was important from a mechanistic standpoint to deter-
mine if CpG-induced IL-12p40 was in fact required for IL-
15+CpG-induced IFN-𝛾𝛾𝛾𝛾 production by CD8+ T cells. To
address this issue, we �rst neutralized IL-12p40 in CD8+T
cell cultures stimulated with anti-CD3, CpG, and/or IL-15.
Clearly, neutralization of IL-12p40 led to a dramatic reduc-
tion in CpG+IL-15-induced IFN-𝛾𝛾𝛾𝛾 production (Figure 3(b)).
Since both IL-12 and IL-23 share the IL-12p40 subunit, we
wanted to con�rm the importance of APC-derived IL-12
in CpG+IL-15-mediated eﬀects on T. cruzi-speci�c CD8+ T
cells. To do so, we used APCs puri�ed from IL12p35−/− mice
(which speci�cally lack IL-12). Similar to results shown in
Figure 3(b), splenocytes from T. cruzi-infected IL12p35−/−
mice failed to exhibit an increase in antigen-speci�c IFN-𝛾𝛾𝛾𝛾
production following IL-15 and CpG treatment (Figure 3(c)).
Furthermore, experiments revealed that addition of recombi-
nant IL-12 recapitulated the eﬀect of CpG (data not shown).
us, the ability of IL-15 and CpG to synergize and enhance
IFN-𝛾𝛾𝛾𝛾 production by T. cruzi-speci�c CD8+ T cells is driven
by CpG-induced IL-12 production by APC.
3.4. Synergy between IL-12 and IL-15 Overcomes Potent Sup-
pression of CD8+ T-Cell Responses by CD4+CD25+ Regulatory
T Cells. Since IL-12 was the primary mediator of the CpG
eﬀect, we next wanted to determine if IL-12 could synergize
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F 4: Synergy between IL-12 and IL-15 overcomes potent suppression of CD8+ T-cell responses by nTreg. (a) CFSE-labeled CD8+ T cells,
APC, and anti-CD3 were cultured in the absence or presence of puri�ed nTreg at a 1 : 1 or 1 : 2 Treg : CD8 T-cell ratio, along with either IL-12,
IL-15, or IL-12+IL-15. Aer 72 hours, cells were analyzed for CFSE dilution by FACS. 30,000 live events were collected, percentages re�ect
the number of CFSElo, or dividing CD8+ T cells (∗∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃, ∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃). (b) 30,000 CD8+ T cells were analyzed to determine the frequency
of CD8+ T cells that had divided either 1–3 or >4 times. Numbers re�ect the percentage of cells accumulated in either group. 𝑃𝑃𝑃𝑃 values for
cytokine-treated wells are relative to Treg suppression controls (no cytokines). ∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for IL-12+IL-15 relative to IL-12; ∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for IL-
12+IL-15 relative to IL-12. In (c), supernatants were harvested from cocultures and analyzed for IFN-𝛾𝛾𝛾𝛾 by ELISA (∗∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃, ∗∗𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃).
Results of one experiment are shown, asterisks represent the statistical signi�cance of each group from at least 4 experiments.
with IL-15 to enhance IFN-𝛾𝛾𝛾𝛾 production when CD8+ T
cells were activated in the presence of CD4+CD25+ Foxp3-
expressing regulatory T cells (nTreg), a T-cell subset well
known for its ability to suppress both CD8+ and CD4+
T cell functions. us, we performed coculture experi-
ments consisting of CFSE-labeled CD8+ T cells, APC, anti-
CD3, and puri�ed nTreg at either a 1 : 1 or 1 : 2 suppres-
sor : responder ratio. In the absence of nTreg, a majority of
anti-CD3-stimulated CD8+ T cells were CFSEdim aer 72
hours (Figure 4(a), 79.7%). In contrast, coculture with nTreg
suppressed CD8+ T-cell proliferation in a concentration-
dependent fashion, reducing the frequency of CFSEdim cells
(Figure 4(a), 40.9% and 47% for 1 : 1 and 1 : 2 ratios,𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
and 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 resp.). In addition to reduced proliferation,
IFN-𝛾𝛾𝛾𝛾 production was suppressed to undetectable levels at
both ratios tested (𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for 1 : 1, 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for 1 : 2,
Figure 4(c)). However, addition of IL-12 to cocultures led to a
signi�cant increase in CD8+ T-cell proliferation (Figure 4(a),
70% and 80.8% for 1 : 1 and 1 : 2 ratios, 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 and
𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 resp.). Furthermore, exogenous IL-12 induced
signi�cant IFN-𝛾𝛾𝛾𝛾 production (Figure 4(c), 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 and 𝑃𝑃𝑃𝑃 𝑃𝑃
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for 1 : 1 and 1 : 2 ratios, resp.). In contrast to IL-12, IL-15
had a modest enhancing eﬀect on proliferation, but did not
reach statistical signi�cance (Figure 4(a)). Similarly, IL-15
alone had no signi�cant eﬀect on IFN-𝛾𝛾𝛾𝛾 production. Despite
these modest eﬀects, however, addition of IL-15 to cocultures
containing IL-12 led to a striking increase in both CD8+ T
cell proliferation (Figure 4(a), 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for both 1 : 1 and
1 : 2 ratios) and IFN-𝛾𝛾𝛾𝛾 production (Figure 4(c), 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃, for
both 1 : 1 and 1 : 2 ratios).
In addition to changes in the frequency of CSFEdim CD8+
T cells (Figure 4(a)), diﬀerences existed in the number of cell
divisions among CFSEdim cells. us, we performed FACS
analysis by gating on live CD8+ T cells and determined the
frequency of cells that had either 1–3 or >4 cell divisions.e
signi�cance of this number is that at least 3 cell divisions are
required before CD8+ T cells express the chemokine receptor
CXCR3, an important phenotypic marker of eﬀector T cells
(unpublished data). e advantage of gating on CD8+ T cells
is that it allows us to account for cells that had lost their CFSE
due to extensive proliferation (>6 cell divisions). A majority
of CD8+ T cells cultured with anti-CD3 divided four or more
times (Figure 4(b), 87% of CD8+ T cells), while only 12% of
CD8+ T cells divided 1–3 times. However, coculture of CD8+
T cells with nTreg led to a signi�cant increase in CD8+ T cells
that had divided only 1–3 times (47.3% and 37.4% for 1 : 1
and 1 : 2 ratios, resp., 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃). When IL-12 was added to
cocultures, however, the number of cells with 1–3 divisions
was reduced to 23.2% and 12.5% (1 : 1 and 1 : 2 ratios, resp.) as
more CD8+ T cells divided >4 times (Figure 4(b), 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃).
Surprisingly, IL-15 was equivalent to IL-12 for its ability to
increase cell division among CFSEdim cells (𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 at 1 : 1,
𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for 1 : 2 ratio). Importantly, the addition of IL-
15 to cocultures with IL-12 caused a signi�cant increase in
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CD8+ T cell division, with only 5% and 3% of CD8+ T cells
with 1–3 cell divisions (Figure 4(b), 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃, 𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
for diﬀerence between IL-12 and IL-12+IL-15 at 1 : 1 ratio,
𝑃𝑃𝑃𝑃 𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 for diﬀerence between IL-12 and IL-12+IL-15 at
1 : 2 ratio). ese results demonstrate that synergy between
IL-12 and IL-15 is eﬀective even in the presence of potent
suppression by nTreg, and that synergy increases not only
the frequency of CFSEdim cells, but also the number of cell
divisions within dividing cells.
3.5. IFN-𝛾𝛾𝛾𝛾 Is Not Required for CpG-Induced IL-12 Produc-
tion. Stimulation with CpG, as well as signals provided by
memory CD8+ T cells such as IFN-𝛾𝛾𝛾𝛾, TNF-𝛼𝛼𝛼𝛼, GM-CSF, and
CD40L can cooperate in a synergistic fashion to promote IL-
12p70 production [20]. For this reason, and because of the
importance of IFN-𝛾𝛾𝛾𝛾 to successful vaccine-induced immune
responses, we wished to determine if IFN-𝛾𝛾𝛾𝛾 was required for
CpG-dependent upregulation of IL-12 by antigen-presenting
cells. us, we stimulated y1.2-depleted splenocytes from
naïve, wild-type, or Ifng−/− mice with CpG for 72 hours and
tested supernatants for IL-12p40 protein. Although the levels
of IL-12p40 were decreased in Ifng−/− cultures relative to
wild-type cultures, there was no statistically signi�cant dif-
ference between the groups (Figure 5(a), le). Additionally,
y1.2-depleted splenocytes from T. cruzi-infected Ifng−/−
mice stimulated with CpG produced as much IL-12p40
as wild-type splenocytes (Figure 5(a), right). ese results
suggest that APC-derived IFN-𝛾𝛾𝛾𝛾 is not absolutely required
for CpG-induced IL-12 production but may be necessary for
optimal expression of IL-12. To further address the role of
IFN-𝛾𝛾𝛾𝛾 in CpG-induced IL-12 by APC, we set up cocultures
consisting of y1.2-depleted splenocytes from wild-type
uninfected mice with puri�ed CD8+ T cells derived from
either wild-type or Ifng−/− mice previously infected with
T. cruzi. As expected, the addition of CpG to anti-CD3-
stimulated cultures led to a strong induction of IL-12p40.
Importantly, CpG-induced IL-12p40 production was not
signi�cantly aﬀectedwhen IFN-𝛾𝛾𝛾𝛾-de�cient CD8+ T cells were
utilized (Figure 5(b)).ese results con�rm that IFN-𝛾𝛾𝛾𝛾 is not
required for IL-12 production by APC in response to CpG
stimulation.
3.6. e Synergistic Eﬀects of IL-15 and CpG Are Dependent
upon T-bet Expression. e T-box transcription factor T-
bet (Tbx21) is critical for eﬀector and memory CD8+ T-
cell function, including IFN-𝛾𝛾𝛾𝛾 production [21]. However,
Eomes (Eomesodermin), a related transcription factor, can
provide overlapping and redundant functions with T-bet
[22]. Given that Eomes has the potential to compensate for
T-bet functions, we wished to determine if the ability of IL-15
andCpG to enhance IFN-𝛾𝛾𝛾𝛾 production by CD8+ T cells could
be maintained in the absence of T-bet. us, CD8+ T cells
from T-bet-de�cient (Tbx21−/−) mice were cocultured with
APC in the presence of IL-15+CpG. Surprisingly, however, T-
bet-de�ciency in CD8+ T cells had a dramatic consequence,
as the ability of IL-15+CpG to synergize and promote IFN-
𝛾𝛾𝛾𝛾 production was lost (Figure 6). ese results demonstrate
that synergy between IL-15 and CpG requires the expression
of T-bet and suggests that Eomes cannot compensate for its
absence.
4. Discussion
Because of their critical role in immunity to tumors, viruses,
and intracellular parasites such as T. cruzi [13–16, 23–
25], a major goal of vaccine development is to harness the
potency of CD8+ T-cell responses. However, a challenge in
developing CD8+ T-cell-based vaccines is the generation of
potent eﬀector T cells as well as long-term memory. One
promising approach is the incorporation of adjuvants that act
as TLR agonists and can augment CD8+ T-cell immunity. For
example, synthetic CpG ODNs that express unmethylated
CpG motifs have been the focus of much attention for
their potential use as vaccine adjuvants due to their ability
to promote type I immunity, including antigen-speci�c T-
and B-cell responses [26]. Recently, common gamma-chain
family cytokines such as IL-15 has also been considered as
candidates for improving vaccine responses. While there are
numerous studies showing the bene�cial eﬀects of CpGor IL-
15, the potential synergy of these two immune modulators
remains to be determined.
In this study, our goal was to determine if IL-15 and CpG
could function in a synergistic manner to promote CD8+ T-
cell responses. We show that CpG alone had the ability to
enhance IFN-𝛾𝛾𝛾𝛾 production by polyclonally activated CD8+ T
cells. However, when CpG and IL-15 were used in combina-
tion, there was a profound and synergistic increase in IFN-
𝛾𝛾𝛾𝛾. e synergistic eﬀect required only low concentrations
of IL-15 that otherwise could not directly induce IFN-𝛾𝛾𝛾𝛾. To
expand upon this observation, we wished to determine if
the synergistic eﬀect could be recapitulated with antigen-
speci�c CD8+ T cells. Splenocytes from T. cruzi-infected
mice restimulated with Tskb20 peptide in the presence of
both CpG and IL-15 showed an increase in IFN-𝛾𝛾𝛾𝛾 production
that was greater than with CpG alone or IL-15 alone. ese
�ndings support the notion that synergy between CpG and
IL-15 can enhance antigen-speci�c CD8+ T-cell responses.
Although synergy was less dramatic with T cells from T.
cruzi-infected mice, we believe the diﬀerence is that Tskb20-
speci�c T cells, which are generated in vivo in response to a
natural infection, have diﬀerentiated under highly stimula-
tory conditions and may be refractory to further stimulation
ex vivo. If true, it would suggest that the eﬃcacy of CpG
and IL-15 may be better suited for preventative vaccines
as opposed to therapeutic vaccines. Nevertheless, synergy
between CpG and IL-15 was evident when used to stimulate
T. cruzi-speci�c CD8+ T cells in the absence of antigen.
Stimulation of APC with CpG promotes their maturation
and increases the production of proin�ammatory cytokines,
especially IL-12, that favor the development of type I immu-
nity [11, 26, 27]. us, we wanted to determine the role of
IL-12 in CpG-mediated synergy with IL-15 on CD8+ T-cell
function. Not surprisingly, we observed that T-cell-depleted
splenocytes from naïve or T. cruzi-infected mice produced
IL-12 in response to stimulation with CpG, whereas IL-15
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F 5: T cell-derived IFN-𝛾𝛾𝛾𝛾 is not required for CpG-induced IL-12 production. (a) y1.2-depleted splenocytes were isolated from the
spleens of naïve (le) or T. cruzi-infected (right) wild-type and Ifng −/− mice on day 9 p.i. y1.2-depleted splenocytes were then stimulated
with CpG. Aer 72 hours, culture supernatants were harvested and tested for IL-12p40 by ELISA. (b)�ild-type (�lled bars) or Ifng −/− (open
bars) CD8+ T cells were puri�ed from the spleens of T. cruzi-infected mice on day 9 p.i. and cocultured with wild-type y1.2-depleted
APC for 72 hours in the presence of anti-CD3 or anti-CD3+CpG. Cell culture supernatants were then harvested and IL-12p40 levels were
determined by ELISA. Results are representative of two independent experiments with two mice per group and are expressed as mean ± SD.
NS: not signi�cant.
had no eﬀect on IL-12 production. Importantly, addition of
IL-15 to CpG-stimulated cultures did not lead to a further
increase in IL-12, suggesting that the synergy between CpG
and IL-15 is not due to IL-15-mediated enhancement of IL-
12 production.is observation is in slight contradiction to a
recent study in which it was shown that IL-15 is important for
CpG-induced IL-12 production by dendritic cells [19]. How-
ever, this discrepancy could be explained by the possibility
that low levels of IL-15 were produced as a result of T. cruzi
infection,making it such that additional treatment with IL-15
could not further enhance CpG-induced IL-12 production.
To determine the importance of this IL-12, we observed that
neutralization of IL-12 abrogated the synergistic eﬀect on
IFN-𝛾𝛾𝛾𝛾 production by CD8+ T cells. Furthermore, antigen-
speci�c CD8+ T cells stimulated in the presence of CpG and
IL-15 produced signi�cantly less IFN-𝛾𝛾𝛾𝛾 when cultured with
IL-12-de�cient APC. us, our results demonstrate that the
enhancement of CD8+ T-cell IFN-𝛾𝛾𝛾𝛾 production provided by
the combination of CpG and IL-15 requires CpG-induced IL-
12.
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In a previous study, it was reported that memory CD8+
T cells are required for APC to produce optimal levels of
IL-12 in response to CpG stimulation [20]. Speci�cally, it
was observed that IFN-𝛾𝛾𝛾𝛾, TNF-𝛼𝛼𝛼𝛼, and GM-CSF produced by
CD44hi memory CD8+ T cells synergized with CpG to prime
dendritic cells for further IL-12 production. For this reason,
we examined whether T cell-derived IFN-𝛾𝛾𝛾𝛾 was necessary
for CpG-induced IL-12 production by APC. However, our
results indicated that IFN-𝛾𝛾𝛾𝛾, regardless of the source, was not
necessary for APC to produce IL-12 in response to CpG stim-
ulation. us, although IFN-𝛾𝛾𝛾𝛾 appeared to be dispensable in
our study, it remains possible that TNF-𝛼𝛼𝛼𝛼 and/or GM-CSF
fromT. cruzi-speci�cmemoryCD8+ T cells could be priming
APC for CpG-induced IL-12 production. Nevertheless, IL-12
is critical for the observed synergistic eﬀects between CpG
and IL-15. e �ndings we report here compliment those
reported by Wysocka et al. [6], in which the bene�cial eﬀects
of CpG and IL-15 were observed following the treatment of
human NK and CD8+ T cells isolated from patients with
cutaneous T-cell lymphoma. Even though analysis of CD8+
T cells was limited to upregulation of CD69 expression, CpG,
and IL-15-augmented IFN-𝛾𝛾𝛾𝛾 production by peripheral blood
mononuclear cells. Numerous studies have shown that CpG
can increase the immunogenicity of vaccines against cancer
and infectious diseases. For instance, CpG can accelerate
the development and enhance the magnitude of vaccine-
induced immune responses. In the case of T. cruzi infection,
CD8+ T cells are critical for host protection. However,
their development is delayed in comparison to other viral
and bacterial infections and this delay has been attributed
to poor TLR stimulation. Indeed, CpG administration in
combination with a TLR-2 agonist signi�cantly accelerated
the development of CD8+ T-cell responses to T. cruzi [28].
us, vaccine approaches against infectious agents will likely
bene�t greatly from the immunostimulatory properties of
CpG.
With respect to the contribution of IL-15, we observed
that IL-15 increases cell division among activated CD8+ T
cells, as well as increases cell viability. is is not a trivial
point. For example, local IL-15 production in the heart of
T. cruzi-infected persons correlates with increased numbers
of CD8+ T cells [29]. Furthermore, an important �nding we
report here is that IL-15 can synergize with IL-12, the main
eﬀector of CpG stimulation, to overcome potent suppression
mediated by CD4+CD25+ regulatory T cells (nTreg). e
combination of IL-15 and IL-12 provided a signi�cant boost
to both CD8+T-cell proliferation and IFN-𝛾𝛾𝛾𝛾 production
despite high numbers of Treg. Since Treg function has been
reported to interfere with immune responses to T. cruzi
[30, 31], this would be another advantage of using CpG and
IL-15 to boost immunity to T. cruzi. We propose that the
ability of IL-15 to promote CD8+ T-cell survival and cell
division, as well as function in the presence of Treg-mediated
suppression, contributes to its eﬀectiveness in synergizing
with CpG. It should be noted that although the eﬀects
described above for IL-15 impact CD8+ T cell numbers, it
was recently reported that IL-15 may enhance expression of
the low-aﬃnity IL-12 receptor 𝛽𝛽𝛽𝛽1 in bothmouse and humans
[32, 33].
To identify the T-cell-intrinsic factors that are important
for the reported eﬀects of CpG and IL-15, we turned our
attention to the transcription factors T-bet and Eomes. T-
bet and Eomes are critical for CD8+ T-cell development
and function [21]. For example, T-bet regulates the gener-
ation of antigen-speci�c CD8+ T cells [17] and promotes
eﬀector functions like IFN-𝛾𝛾𝛾𝛾 production [34]. Likewise,
Eomes performs similar functions such as promoting the
production of cytotoxic eﬀector molecules and IFN-𝛾𝛾𝛾𝛾 [22].
Here, we demonstrate that T-bet is required for the syner-
gistic enhancement of IFN-𝛾𝛾𝛾𝛾 production by CpG and IL-15.
Although Eomes can compensate for many of the functions
of T-bet in CD8+ T cells [21], it did not appear to mediate
the synergistic eﬀect of CpG and IL-15 and their ability to
enhance IFN-𝛾𝛾𝛾𝛾 production. erefore, T-bet expression in
CD8+ T cells is critical for the bene�cial eﬀects of CpG and
IL-15 treatment.
In summary, we propose that CpG causes APC to release
IL-12, a powerful cytokine that serves as “Signal 3” for
CD8+ T cells. However, the IL-12 cannot act unless T
cells are activated and express the appropriate receptor to
respond to IL-12. IL-15, in addition to its ability to promote
CD8+ T-cell survival and proliferation, may enhance T-cell
responsiveness to IL-12 and thus increase IFN-𝛾𝛾𝛾𝛾. We believe
the synergy will enhance both immediate and long-term
CD8+ T-cell responses. is has great potential in clinical
trials, because CpG do not appear to have the same toxicity as
treatment with exogenous IL-12, which has been reported in
cancer patients despite positive therapeutic eﬀects. In terms
of IL-15, adoptive transfer of T cells into a lymphopenic
tumor-bearing host (which typically occurs aer whole body
irradiation) leads to increased IL-15-dependent proliferation,
expansion, and CD8+ T-cell eﬀector function. e results
of our study provide additional evidence of the potential
eﬃcacy of CpG and IL-15 and how it may improve vaccine
approaches against cancer and infectious diseases. Not only
BioMed Research International 11
do we demonstrate that CpG and IL-15 are more eﬀective
when used in combination, but our �ndings also provide
new insight into the immunemechanisms responsible for the
observed synergy between CpG and IL-15. Because of the
considerable interest in TLR agonists as vaccine adjuvants,
we believe our study will provide additional evidence that
TLR agonists, when combined with common gamma chain
cytokines, have the potential to dramatically enhance vaccine
eﬃcacy.
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